These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21151870)

  • 1. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.
    Peng H; Qi J; Dong Z; Zhang JT
    PLoS One; 2010 Dec; 5(12):e15276. PubMed ID: 21151870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
    Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
    PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New use for an old drug: inhibiting ABCG2 with sorafenib.
    Wei Y; Ma Y; Zhao Q; Ren Z; Li Y; Hou T; Peng H
    Mol Cancer Ther; 2012 Aug; 11(8):1693-702. PubMed ID: 22593228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
    Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
    Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
    Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
    Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
    Narayanan S; Gujarati NA; Wang JQ; Wu ZX; Koya J; Cui Q; Korlipara VL; Ashby CR; Chen ZS
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Kathawala RJ; Chen JJ; Zhang YK; Wang YJ; Patel A; Wang DS; Talele TT; Ashby CR; Chen ZS
    Int J Oncol; 2014 May; 44(5):1634-42. PubMed ID: 24626598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
    Holland ML; Lau DT; Allen JD; Arnold JC
    Br J Pharmacol; 2007 Nov; 152(5):815-24. PubMed ID: 17906686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.